摘要
子宫颈胃型腺癌(G-EAC)是一种特殊的非HPV相关型腺癌(NHPVA),发病率逐年上升,常规筛查检出率低,早期症状不典型,确诊时多数患者已处于疾病晚期并伴随远处转移,预后极差.G-EAC的临床不良预后与其独特的分子病理特征有关,特异性表达且具有预后价值的生物标志物将有助于临床预后评估、指导个体化治疗,改善患者的生存结局.然而,目前可用于评估G-EAC预后的生物标志物仍需进一步探索.G-EAC癌组织或基质中表达的蛋白PAX-8、Smad3、p53、CA-IX、HER-2、STK11、p16和PD-L1等生物标志物可能与G-EAC转移、不良预后、复发风险密切相关.该文就子宫颈胃型腺癌表达预后相关生物标志物的国内外研究进展进行综述.
Abstract
Gastric-type endocervical adenocarcinoma(G-EAC)is a special type of non-human papillomavirus(HPV)-associated adenocarcinoma with an increasing incidence rate,a low detection rate in routine screening and atypical early symptoms.When diagnosed,most patients are already in the advanced stage with local and distant metastasis and thus the prognosis is extremely poor.The poor clinical prognosis of G-EAC is related to its unique molecular pathological features,and biomarkers with specific expression and prognostic value would be helpful for assessment of clinical prognosis,guidance of individualized treatment,and improvement of patient survival outcomes.However,biomarkers currently available for assessing the prognosis of G-EAC still require further exploration.Biomarkers such as proteins PAX-8,Smad3,p53,CA-IX,HER-2,STK11,p16,and PD-L1,which are expressed in the cancer tissues or stroma of G-EAC,may be closely associated with the risk of metastasis,poor prognosis,and recurrence of G-EAC.In this review,we summarize the domestic and international research progress on prognostic biomarkers expressed in G-EAC.
基金项目
贵州省科技计划项目(黔科合基础-ZK[2022]一般436)
贵州医科大学附属医院博士科研启动基金(gyfybsky-2023-21)
贵州医科大学附属医院新年培育项目(I-2020-36)
维普
万方数据